Overview
- Ozempic is available in 0.25 mg, 0.5 mg and 1 mg FlexTouch pens, priced at ₹8,800, ₹10,170 and ₹11,175 per month respectively, with each pen covering four weekly doses.
- India’s regulator approved semaglutide in October for adults with type 2 diabetes as an adjunct to diet and exercise, with evidence of HbA1c reduction, weight benefits and cardiovascular and kidney protection.
- Novo Nordisk says Indian supplies will be imported from Denmark, with distribution planned across major cities and diabetes clinics.
- Endocrinologists advise use only under medical supervision, noting common side effects such as nausea and vomiting and cautioning to rule out pancreatitis or gallbladder issues and to avoid cosmetic or micro-dosing use.
- Patent dynamics shape near-term access: a core patent expired in 2024, a secondary patent runs to March 2026, courts have allowed manufacture for export but restricted domestic sales by others, and generic entry is anticipated after March 2026.